Baseline first positron emission tomography (PET)/computed tomography (CT) scan: positive 2-deoxy-2-(fluorine-18) fluoro-d-glucose (18F-FDG) PET/CT extrapulmonary disease sites in 358 patients

PET/CT-positive patients n (%)SUVmax
Brain34 (9.5)4.0–
Cardiac2 (0.6)3.2–
Pleura34 (9.5)2.6–
Muscles#10 (2.8)2.8–
Liver7 (2.0)3.8–23.312.413.1
Spleen11 (3.1)2.7–
Gastrointestinal tract8 (2.2)3.4–
Urogenital tract7 (2.0)2.6–16.99.710.0
Bone151 (42.2)2.5–
Lymph nodes225 (62.8)2.8–32.310.79.9
 Cervical108 (30.2)2.6–
 Supraclavicular69 (19.3)3.1–
 Axillary51 (14.2)2.5–
 Mediastinal152 (42.4)2.5–
 Hilar70 (19.6)2.7–
 Retrocrural9 (2.5)2.7–
 Retroperitoneal/mesenteric55 (15.4)3.0–
 Pelvic28 (7.8)2.5–
 Inguino-femoral18 (5.0)2.5–
Other sites21 (5.9)2.5–

Some patients had more than one organ involved. SUVmax: maximum standardised uptake value; SUVmax is a relative measure of FDG metabolism: Embedded Image; r: radioactivity concentration (kBq·mL−1); a′: decay-corrected amount of radiolabelled FDG (kBq); w: weight of patients (g). #: iliopsoas n=4, pectoral muscle n=1, posterior intercostal n=1, gluteal n=2, thigh n=1, obturator internus n=1; : paravertebral mass/collection n=12 (SUVmax 2.5–9.8), adrenals n=3 (SUVmax 3.9–6.5), joint effusions n=3 (SUVmax 12.9–32), endometrium/ovary n=2 (SUVmax 4.1–7.1), focal bone marrow lesion n=1 (SUVmax 5.2).